The Company previously had received a notice from the staff of Nasdaq that the staff was recommending the delisting of the Companys common stock. Pursuant to that notice (which was previously filed with the SEC on form 8-K) the Company requested a hearing on the delisting recommendation, which hearing was held on November 10, 2016. On December 21, 2016, the Company received a letter from the Hearing Panel stating that the Company securities will be suspended from trading effective at the opening of business on December 23, 2016. The Hearing Panel determined that the Company delisting is pursuant to listing rule 5101 and 5250(a)(1).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DS HEALTHCARE GROUP, INC.
Date: December 21, 2016
Chief Financial Officer
makes a similar move, sign up!